Results for this period
First quarter1 July 2026–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Research and development expenses increased by ¥47 million from the same quarter of the previous year to ¥329 million, selling, general and administrative expenses increased by ¥3 million to ¥81 million, and operating expenses increased by ¥50 million to ¥411 million. Non-operating income and expenses included ¥1 million in interest income and a ¥16 million foreign exchange loss.
There are no matters to report under the going concern assumption. However, the company states that circumstances exist that raise significant doubt about the going concern assumption, including the absence of business revenue from product sales and the lack of partnership arrangements.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 July 2026–30 September 2026 |
| Operating profit | ¥-411 million |
| Ordinary income | ¥-426 million |
| Profit attributable to owners of the parent | ¥-426 million |
| Net income per share | -¥21.65 |
| Equity ratio | End of the current fiscal period 89.1% / End of previous period 90.2% |
| Total assets | ¥1,320 million |
| Net assets | ¥1,218 million |
| Cash and cash equivalents at end of period | ¥1,078,988 thousand |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Disclosure regarding the going concern assumption | There are no matters to report under the going concern assumption. However, the company states that circumstances exist that raise significant doubt about the going concern assumption, including the absence of business revenue from product sales and the lack of partnership arrangements. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | On 30 October 2026, the company issued the 22nd, 23rd and 24th Series Stock Acquisition Rights through a third-party allotment, totaling 48,000 rights and covering 4,800,000 shares, with total issue proceeds of ¥15,140,000. On 2 November 2026, it entered into a basic agreement for a committed credit facility with SBI Securities, with a borrowing limit of ¥500 million. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 19,713,655 shares |
| Treasury Shares at Period-End | 10,598 shares |
| Factors Behind Changes in Business Performance | Research and development expenses increased by ¥47 million from the same quarter of the previous year to ¥329 million, selling, general and administrative expenses increased by ¥3 million to ¥81 million, and operating expenses increased by ¥50 million to ¥411 million. Non-operating income and expenses included ¥1 million in interest income and a ¥16 million foreign exchange loss. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses increased by ¥47 million from the same quarter of the previous year to prepare for the start of the European Phase 3 clinical trial of CBP501 and for the preclinical trials of CBT005. Selling, general and administrative expenses also increased by ¥3 million. In addition, a foreign exchange loss of ¥16 million was recorded in the quarter.